Newly designed ۲-(aminomethyl)benzimidazole derivatives as possible tyrosine kinase inhibitors: synthesis, characterization, preliminary cytotoxic evaluation and in Silico studies
- سال انتشار: 1403
- محل انتشار: مقالات مروری و پژوهشی شیمی، دوره: 7، شماره: 5
- کد COI اختصاصی: JR_CHRL-7-5_005
- زبان مقاله: انگلیسی
- تعداد مشاهده: 85
نویسندگان
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Iraq
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Iraq
Faculty of Allied Medical Sciences, Applied Science Private University, Amman, Jordan
چکیده
Benzimidazole is an isostere of purine nucleosides so; it is widely used as a basic nucleus in the development of different anticancer agents. Receptor tyrosine kinases (RTK) was found with high overexpression in many of aggressive cancer types. So, they are considered as important targets in cancer therapy. However, many of molecular mechanisms of resistance have been identified leading to multi-drug resistance thereby, as increase the need to discover new anticancer therapies. In this study, a set of ۲- (amino methyl) benzimidazole derivatives were designed and docked virtually then were synthesized, characterized and studied their preliminary structure-activity relationship for cytotoxic activities for two cancer cell lines (breast and lung cancer) as well as Vero normal cells, using gefitinib as a reference standard. Most of the synthesized compounds were active against T۴۷D cell line, and both ۴g and ۲g compounds give higher cytotoxicity than gefitinib, while A۵۴۹ cell line showed a highly resistance to all compounds even gefitinib. More interesting, all synthesized compounds were inactive against normal cells. The docking score results of the synthesized compounds were compatible to their cytotoxic activity, this evidence gives a good explanation that they could act as receptor tyrosine kinase inhibitors (RTKIs). ADME study of the highly cytotoxic compounds with gefitinib was done with good drug likeness and pharmacokinetic results.کلیدواژه ها
new benzimidazole derivatives, tyrosine kinase inhibitors (TKIs), cytotoxic study, docking studyاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.